Mebeverine: Difference between revisions
m Protected "Mebeverine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 26: | Line 26: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
'''Mebeverine HCI''' is a musculotropic [[antispasmodic]] drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by [[Solvay (company)|Solvay Pharmaceuticals]]. | '''Mebeverine HCI''' is a musculotropic [[antispasmodic]] drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by [[Solvay (company)|Solvay Pharmaceuticals]]. | ||
| Line 38: | Line 38: | ||
[[Category: Motility stimulants]] | [[Category: Motility stimulants]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:14, 9 August 2012
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C25H36NO5 |
| Molar mass | 430.5595 g/mol |
|
WikiDoc Resources for Mebeverine |
|
Articles |
|---|
|
Most recent articles on Mebeverine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Mebeverine at Clinical Trials.gov Clinical Trials on Mebeverine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mebeverine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mebeverine Discussion groups on Mebeverine Patient Handouts on Mebeverine Directions to Hospitals Treating Mebeverine Risk calculators and risk factors for Mebeverine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mebeverine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Mebeverine HCI is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by Solvay Pharmaceuticals.
Mebeverine HCI presented in tablets (100mg or 135mg), capsules (200mg slow release), and liquid (10mg/ml).
Mode of Action
Mebeverine HCI belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.
Template:Drugs for functional gastrointestinal disorders
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Motility stimulants